Table 3.
Multivariable models evaluating factors associated with levels of AST and ALT among TM and CF study participants
|
AST
|
ALT
|
|||
|---|---|---|---|---|
| Parameter of interest | Difference (%) | 95% CI | Difference (%) | 95% CI |
| Gender identity (TM vs CF) | 6 | −2, 15 | 7 | 2, 13 |
|
| ||||
| Site (KPNC vs other) | 4 | 0, 8 | 8 | 6, 12 |
|
| ||||
| Age group (y) vs 18–25 | ||||
|
| ||||
| 26–35 | 1 | −4, 5 | 1 | −3, 5 |
|
| ||||
| 36–45 | 3 | −2, 8 | 3 | 0, 7 |
|
| ||||
| 46–55 | 8 | 3, 15 | 12 | 7, 17 |
|
| ||||
| 56+ | 21 | 15, 28 | 17 | 13, 22 |
|
| ||||
| Race/ethnicity (vs NHW) | ||||
|
| ||||
| Non-Hispanic Black | −2 | −7, 4 | −12 | −16, −8 |
|
| ||||
| Hispanic | 8 | 3, 13 | 7 | 3, 11 |
|
| ||||
| Asian/Pacific Islander | 1 | −5, 8 | −1 | −5, 4 |
|
| ||||
| Other/Unknown | −3 | −11, 6 | 1 | −5, 8 |
|
| ||||
| Body mass index (kg/m2) ≥25.0 vs <25.0 | 3 | −1, 6 | 21 | 19, 25 |
|
| ||||
| Alcohol use/abuse (yes vs no) | 11 | 6, 15 | 12 | 7, 15 |
|
| ||||
| Time (10-d increments) | ||||
|
| ||||
| Pre-GAHT | 2 | −2, 5 | −2 | −5, 1 |
|
| ||||
| Post-GAHT | −5 | −15, 6 | 1 | −6, 8 |
|
| ||||
| Pre-GAHT × gender identity | 13 | −4, 31 | 17 | 4, 31 |
|
| ||||
| Post-GAHT × gender identity | 39 | −12, 120 | 62 | 21, 116 |
|
| ||||
| Calculated adjusted average 10-d change (%) | ||||
|
| ||||
| TM pre-GAHT | 15 | −1, 33 | 15 | 2, 28 |
|
| ||||
| TM post-GAHT | 52 | 4, 122 | 88 | 49, 136 |
|
| ||||
| CF pre-GAHT | 2 | −2, 6 | −2 | −5, 1 |
|
| ||||
| CF post-GAHT | −3 | −11, 6 | −1 | −6, 4 |
|
| ||||
| Ratio-of-ratios for 10-d change among TM (post- vs pre-GAHT) | 1.32 | 0.85, 2.06 | 1.64 | 1.24, 2.17 |
|
| ||||
| Ratio-of-ratios for post-GAHT 10-d change (TM vs CF) | 1.57 | 1.06, 2.31 | 1.90 | 1.50, 2.40 |
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CF = cisgender females; CI = confidence interval; GAHT = gender affirming hormone therapy; KPNC = Kaiser Permanente Northern California; TM = transmasculine, NHW = non-Hispanic White.